Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of 12-Week Administration Of PF-00734200 To Subjects With Type 2 Diabetes Mellitus And Insufficient Glycemic Control On Metformin Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Gosogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 28 Mar 2012 Additional trial location added as reported by European Clinical Trials Database.
- 01 Feb 2011 Actual end date changed from Sep 2008 to Aug 2008 as reported by ClinicalTrials.gov.
- 03 Aug 2009 Results reported at ADA 2009.